Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | MDS: an update on pevonedistat plus azacitidine

Mikkael Sekeres • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine Pevonedistat

Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, gives an update on trials testing a combination treatment of pevonedistat and azacitidine in patients with myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Mikkael Sekeres

1:20
Outcomes for Hispanic patients with ALL treated at centers across the US
Mikkael Sekeres • 11 Dec 2021
2:06
Updates from the NHLBI-MDS Natural History study
Mikkael Sekeres • 11 Dec 2021
1:58
Updates from the PANTHER trial
Mikkael Sekeres • 11 Dec 2021
1:34
Exciting news at the ASH 2021 plenary scientific session
Mikkael Sekeres • 6 Dec 2021

Related Videos

2:06
Understanding the role of inflammation and the immunome in MDS pathophysiology
Shahram Kordasti • 5 Apr 2024
2:53
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti • 5 Apr 2024
2:37
Allo-SCT in older patients with MDS: selection, donors, and timing
Didier Blaise • 4 Apr 2024
1:08
Chronological age no longer dictates eligibility for allogeneic transplantation in patients with MDS
Didier Blaise • 4 Apr 2024
The content of VJHemOnc is intended for healthcare professionals